Evidence map›Paper›PMID 41778705›Full record

ReviewYeast (Chichester, England)

The Multifaceted Role of Rad9 in the DNA Damage Response of Saccharomyces cerevisiae.

A Kiely, F O'Halloran, P Young, N F Lowndes, M Grenon, K Finn

Abstract readReview
In one paragraph

Review in Yeast (Chichester, England). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. TPI and GAPDH Interact with Rad9, Linking Glycolytic Enzymes to Cancer.International journal of molecular sciences · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

A KielyDepartment of Biological Sciences, Munster Technological University, Bishopstown, Cork, Ireland.
F O'HalloranDepartment of Biological Sciences, Munster Technological University, Bishopstown, Cork, Ireland.
P YoungSchool of Biochemistry and Cell Biology, University College Cork, Cork, Ireland.
N F LowndesSchool of Biological and Chemical Sciences, College of Science & Engineering, University of Galway, Galway, Ireland.
M GrenonSchool of Biological and Chemical Sciences, College of Science & Engineering, University of Galway, Galway, Ireland.ORCID 0000-0002-9910-5974
K FinnDepartment of Analytical, Biopharmaceutical and Medical Sciences, School of Life Sciences, Faculty of Science and Health, Atlantic Technological University, Galway, Ireland.ORCID 0000-0002-5631-9710

Funding

Munster Technological UniversityScience Foundation Ireland 07/IN.1/B958
6 · The paper itself

Abstract

To maintain the integrity of the genome, cells have evolved a complex signalling system, termed the DNA damage response (DDR), which detects DNA damage and promotes DNA repair. To date, over 600 proteins have been identified that play an integral role in the DDR. RAD9, encoding a DDR mediator protein, was the prototypical DNA damage checkpoint gene, establishing the genetic regulation of transient cell-cycle delays upon DNA damage. Rad9, identified 38 years ago in the budding yeast Saccharomyces cerevisiae as a damage-dependent cell-cycle regulator, is now known to regulate additional responses to DNA damage including both cell-cycle recovery and repair. The Rad9 protein is extensively phosphorylated both during a normal cell cycle and following DNA damage and several of these modifications have been linked to specific Rad9 roles within the DDR. Proteins structurally and functionally related to Rad9 exist in mammalian cells (e.g., 53BP1, BRCA1, MDC1) and insights into their regulation and mechanism of action have been informed by studies in yeast. This review will discuss the cellular mechanisms governing the DDR with an emphasis on the multifaceted role of Rad9 in sensing and responding to DNA damage, and how phosphorylation events regulate its function within the DDR. As the cellular events governing the DDR are well conserved, discoveries in yeast can be extrapolated to humans and may lead to the identification of additional novel protein targets, with several DDR inhibitors currently in clinical use or showing promise in clinical trials.

Indexed as

Cell Cycle ProteinsDNA DamageDNA RepairSaccharomyces cerevisiaeSaccharomyces cerevisiae ProteinsPhosphorylationSignal TransductionCell Cycle Proteinsrad9 proteinSaccharomyces cerevisiae ProteinscancerDNA damage checkpointDNA damage responseDNA repairdouble‐strand breaksRad9

Identifiers

PMID41778705
PMCPMC13067819

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.